Pharmacology Preconference Workshop 2021
Pharmacology and the Future of Managing the HF Patient

7:45-8:00  Registration/Welcome

8:00 – 9:30  The Past, Present and Future Pharmacologic Management of Patients with Heart Failure (1 1/2 hour)
Speaker: Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCN, FHFS, FAAN

1. Describe the past, present and future pharmacologic management of heart failure.
2. Based on current evidence, highlight the challenges we face regarding pharmacologic management.
3. Highlight current recommendations and the role of personalize management of patients with heart failure.
4. Given a patient with heart failure, develop a personalized therapeutic plan to include future advances in pharmacologic management.

9:30 – 10:30  Surviving COVID-19: What do I tell my patients? (1 hour)
Speaker: Matthew Miller, PharmD

1. Describe the pathophysiology of COVID-19 and mutations.
2. Highlight management and evidence-based treatment for the management of patients with COVID and heart failure.
4. Review the various vaccination options that are currently available as well as their pros and cons.

10:30 – 10:45  Break

10:45-11:30  What is the Best Options when the Lipids are elevated? (45 min)
Speaker: Joseph Saseen, PharmD

1. Based on the 2018 Cholesterol Guidelines, highlight specific recommendations regarding patients with heart failure.
2. Highlight recent literature regarding targeted goal LDL for secondary cardiovascular prevention.
3. Given a patient with hyperlipidemia and heart failure, develop a therapeutic plan for the management of the patient’s hyperlipidemia.
Managing Patients with Heart Failure Remotely (30 mins)
Speakers: Karen Vuckovic, PhD, Marilyn A. Prasun, PhD, CCNS, CHFN, FAHA & Robert Page PharmD

1. Given a patient with heart failure and comorbidities who report a change in symptoms that is being managed remotely identify the pharmacological management of this patient and the implications of remote assessment.
2. Given a patient with heart failure and co-morbidities, develop a personalized therapeutic plan for management while considering the impact of the pandemic.

Lunch (Non-CE session)

Cardio-Oncology: What Do I Need to Know? (1 hour)
Speaker: JoEllen Rodgers, PharmD

1. Highlight the pathophysiology and mechanisms for common cardio-toxic chemotherapeutic agents.
2. For specific cardiotoxic chemotherapeutic agents, provide specific monitoring and potential prevention strategies.
3. Identify sources of information that could be helpful to a practitioner who manages a patient with HFrEF and receiving a potentially cardio-toxic chemotherapeutic agent.

SGLT2-Inhibitors and the HFrEF Patient: The Next Generation in HF Medications (45 mins)
Speaker: Orly Vardeny, PharmD

1. Based on current evidence, highlight the potential mechanism of action, pharmacokinetics, drug-drug interactions, and side effects associated with the SGLT2-inhibitors in the management of the patient with HFrEF.
2. Delineate when to initiate a SGLT-2 inhibitor in the management of the HFrEF patient.
3. Given a patient with HFrEF, develop a therapeutic plan that specially includes an SGLT2-inhibitor.

Interesting Cases (1 hour)
Speaker: Chris Bell, ACNP

1. Given a patient with heart failure and a large comorbidity burden, identify specific issues in the pharmacological management of this patient.
2. Given a patient with heart failure and a large comorbidity burden, develop a therapeutic plan for the management of the patient’s heart failure.

Questions & Testing Your Knowledge
Speakers: Robert Page PharmD & Marilyn A. Prasun PhD, CCNS

1. Highlight key information regarding the pharmacologic management of patients with heart failure.

(Non-CE session to follow 1 hour)